NASDAQ: QLI - Qilian International Holding Group Limited

Yield per half year: -10.14%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Qilian International Holding Group Limited


About Qilian International Holding Group Limited

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company offers licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.

more details
It also provides Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

IPO date 2021-01-12
ISIN KYG7307E1070
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 0
Дивиденд ао 0.25
Сайт https://ir.qlsyy.net
Цена ао 7.18
Change price per day: 0% (7.18)
Change price per week: 0% (7.18)
Change price per month: 0% (7.18)
Change price per 3 month: 0% (7.18)
Change price per half year: -10.14% (7.99)
Change price per year: +940.58% (0.69)
Change price per 3 year: +310.29% (1.75)
Change price per year to date: 0% (7.18)

Underestimation

Title Value Grade
P/S 2.96 6
P/BV 3.09 5
P/E 127.83 1
EV/EBITDA -89.12 0
Total: 3.88

Efficiency

Title Value Grade
ROA, % -15.18 0
ROE, % -18.18 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0.5 5
Total: 3.57

Debt

Title Value Grade
Debt/EBITDA -0.3939 10
Total: 8.2

Growth impulse

Title Value Grade
Yield Revenue, % 0.8058 1
Yield Ebitda, % -117.46 0
Yield EPS, % -242.81 0
Total: 2.2

Institutions Volume Share, %
Geode Capital Management, LLC 23641 0.07
UBS Group AG 3357 0.01
Morgan Stanley 1794 0.01



Head Job title Payment Year of birth
Mr. Zhanchang Xin Chairman of the Board, President, COO & Chief Scientific Officer 17.94k 1967 (58 years)
Mr. Chen Xin Chief Executive Officer 1993 (32 years)
Ms. Yaxuan Zhai Chief Financial Officer 1995 (30 years)

Address: China, Jiuquan, Jiuquan Economic and Technological Development Zone - open in Google maps, open in Yandex maps
Website: https://ir.qlsyy.net